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On the basis of 32P-postlabeling analysis, treatment of rats with 1-nitropyrene (1-NP) resulted in the formation of multiple DNA adducts in the liver,
mammary glands, and peripheral lymphocytes. The one adduct resulting from nitroreduction, N-(deoxyguanosin-8-yl)-1-aminopyrene, constitutes
only a minor component among the adducts. In the present study, incubation of calf thymus DNA with mutagenic ring-oxidized metabolites of 1-NP
in vitro in the presence and absence of xanthine oxidase also resulted in the formation of multiple adducts. On the basis of their chromatographic
behavior, it appears that DNA adducts derived from such metabolites may have been formed in vivo; however, this needs to be confirmed. [3H]1-NP
was given to male and female F344 rats and Sprague-Dawley rats by gavage at five dose levels in the range of 0.1 to 1000 pg/kg bw. This led
to stable hemoglobin adducts accounting for 0.08 ± 0.05% of the dose (n = 3 rats). The radioactivity associated with hemoglobin following adminis-
tration of [3H]1-NP was cleared with a half-life of about 14 days, which is faster than that of unmodified erythrocytes in the rat (t1/2= 30 days).
Treatment of the hemoglobin with 1% HCI in acetone, to precipitate the globin, released the radioactivity; it was all bound to the heme moiety. The
structures of the heme adducts have not been elucidated; yet, because of their stability, they may be useful as dosimeters for human exposure to
1-NP. The results of this study demonstrate the potential of using hemoglobin adducts of 1-NP as dosimeters of uptake and metabolic activation of
nitropolynuclear aromatic hydrocarbons (NO2-PAH). These indicators are a prerequisite for cancer risk assessment of N02-PAH. - Environ Health
Perspect 102(Suppl 6):31-37 (1994)
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Introduction
Nitropolynuclear aromatic hydrocarbons
(NO2-PAH) are widely distributed in the
environment (1). Mutagenic activities in
bacterial and mammalian systems and
tumorigenic activity in laboratory animals
of several members of the class of NO2-
PAH have been clearly documented (2-5).
Risk assessment associated with human
exposure to N02-PAH has not been clearly
defined, despite the widespread occurrence
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of such agents in the environment and
their possible involvement in the etiology
of some human cancers (6). Thus, our
goal was to develop sensitive analytical
methods for detection and quantitation of
N02-PAH and their metabolites in biologic
fluids and assessment oftheir adducts with
proteins and DNA in humans. Establishing
the metabolic profiles of 1-nitropyrene (1-
NP) in laboratory animals would be essen-
tial for developing sensitive methods for
their detection and quantitation in
humans. In the mammalian system, 1-NP
is metabolized by nitroreduction, ring oxi-
dation, and a combination of both path-
ways (Figure 1). Studies in our laboratory
and elsewhere indicate that simple nitrore-
duction of 1-NP to yield N-(deoxy-
guanosin-8-yl)-1-aminopyrene (N-dG-AP)
cannot account for the observed DNA
adducts in vivo and in vitro (7-12). To
more clearly define the metabolic activation
of 1-NP, structural elucidation of DNA
adducts is required. Therefore, some ofour
previous efforts were directed towards the
identification of additional DNA adduct
markers derived from ring-oxidized
metabolites of 1-NP (13). Seeking a highly
sensitive method, we used the 32P-postlabel-
ing technique (14) to establish fingerprints
ofthe DNA adducts derived from ring-oxi-
dized metabolites of 1-NP in vitro. The
resulting 32P-postlabeled adducts were
compared with those obtained from rat tis-
sues such as liver, mammary tissues, and
peripheral lymphocytes following the
administration of 1-NP (12). In this study,




Commercial 1-NP (Aldrich Chemical Co.,
Milwaukee, WI) was purified by column
chromatography on silica gel with elution
by 10% benzene in hexane. Its purity,
assessed by GC with electron capture
detection (15) and GC-MS analysis, was
>99.9%; no dinitropyrenes were detected.
1-Nitrosopyrene (1-NOP) was synthesized
by oxidation of 1-aminopyrene (1-AP)
using m-chloroperoxybenzoic acid
(mCPBA) as described (16). 1-Nitro-x-
hydroxypyrene (1-NP-x-OH, x = 3, 6, or
8) was obtained by nitration of 1-acetoxy-
pyrene followed by deacetylation (16).
Refluxing of 1-NP with mCPBA in
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Figure 1. 1-Nitropyrene metabolites (1-13) identified in vivo or in vitro. Acetylation of the amino functionality and
conjugation (glucuronide and sulfates) of C-hydroxylated metabolites have also been demonstrated in vivo.
CH2Cl2 yielded 4,5-epoxy-4,5-dihydro-1-
nitropyrene (1-NP-4,5-oxide) and 9,10-
epoxy-9, 1 0-dihydro- 1 -nitropyrene
(1-NP-9,10-oxide) (17). cis- and trans-4,5-
Dihydro- 4,5-dihydroxy-1-nitropyrene (cis-
and trans-1-NP-4,5-DHD) were also syn-
thesized (18). [14C]1-NP was synthesized
in our laboratory with >99% radiochemical
purity, and a specific activity of 5
mCi/mmole (19). A sample of [3H] 1-NP
(13.7 Ci/mmole) was acquired from
Chemsyn (Lenexa, KS), and pure samples
were obtained by silica gel thin-layer chro-
matography with benzene as eluent; purity
was >99.0% as ascertained by reverse-
phase HPLC and by monitoring radioac-
tivity with a radioflow detector. [3H] 1-
NOP and [3H] 1-NP-4,5-oxide were also
prepared in our laboratory (11,13) as was
2 N-dG-AP (12). The three major N2-
deoxyguanosine adducts derived from 1-
NP-4,5-oxide were synthesized and
structurally characterized (13).
Calf thymus DNA (type I), enzymes
and other biochemical reagents were pur-
chased from Sigma Chemical Co. (St.
Louis, MO). Carrier-free [y-_32P]ATP
(-5000 Ci/mmole, Amersham) and T4
polynucleotide kinase (30 units/ml, U.S.
Biochemical Corp., Cleveland, OH) were
purchased from commercial sources.
Instrumentation
HPLC was performed with a Waters
Associates high-performance liquid chro-
matograph (Millipore, Waters Division,
Milford, MA) equipped with a model 510
solvent delivery system, a model U6K sep-
tumless injector, a model 440 ultraviolet-
visible detector and a model 680 automated
gradient controller. HPLC conditions are
described in the figure legends. A radioflow
detector (Flo-One/Beta, Radiomatic
Instruments and Chemicals Co., Tampa,
FL) was employed in the radiochromatog-
raphy. Quantitative measurements of
radioactivity were made on a Beckman LS
9800 series liquid scintillation counter.
DNABinding Studies in Vitro
Calfthymus DNAwhich had been modified
with 1-NP-4,5-oxide (10,13), or with 1-NP
in the presence of xanthine oxidase (12),
was enzymatically hydrolyzed to 3'-mono-
phosphates followed by 32P-postlabeling.
trans-1-NP-4,5-DHD, 1-NP-x-OH (x = 3,
6, or 8), and 1-NP-9,10-oxide were each
incubated with calf thymus DNA in the
presence or absence ofxanthine oxidase as
reported (20,21). DNA which had been
modified with ring-oxidized metabolites of




Dose-Response Study. Five groups ofthree
male F344 rats weighing 272 ± 6 g
(Charles River Breeding Laboratories,
Kingston, NY) were given [3H]1-NP in
predistilled trioctanoin by gavage. They
were housed under standard conditions
(15) and given tap water and NIH-07 diet
ad libitum. The compound was adminis-
tered at dose levels of 0.1, 1.0, 10, 100,
and 1000 pg/kg bw. Each rat was given 15
pCi, except for the lowest dose, in which
case 2.2 pCi was administered. Twenty-
four hours after gavaging, the rats were
anesthetized with ether or halothane, and
blood was obtained by cardiac puncture
(average 8 ml/rat representing approxi-
mately 50% of the total blood volume)
(22). The blood was drawn into syringes
containing 0.1 ml EDTA solution, 0.25
M, pH 7.4, to prevent clotting. It was then
transferred into polypropylene centrifuge
tubes (35 ml) and placed on ice. All subse-
quent steps were carried out at 4°C. The
blood was centrifuged at 900g to pack the
red blood cells (RBC). The supernatant
plasma was drawn off with a Pasteur
pipette and processed as described below.
The RBC were washed twice with 15-ml
portions of 0.9% saline and centrifuged at
900g each time. The supernatant was kept
frozen. Cell rupture and release of hemo-
globin was minimal as evidenced by the
slight coloration of the supernatant. The
RBC were then lysed by vortexing with 15
ml ice-cold distilled H20 for 5 min. Ten
milliliters of 0.67 M KH2PO4 buffer, pH
6.5, were added, and the solution was cen-
trifuged at 27,000gfor 20 min. The super-
natant containing the hemoglobin was
placed into dialysis tubes (Spectra/Por 4,
14x 103 molecular weight cutoff,
Spectrum Medical Industries, Los Angeles,
CA) and was dialyzed against distilled
H20, 2.5 liters x 4 changes over 4 days.
The hemoglobin solutions were frozen at
-20°C until analysis. The hemoglobin
obtained from each rat was analyzed indi-
vidually. Five-milliliter aliquots ofeach test
solution were placed in scintillation vials
containing 0.5 ml 10 N NaOH; these vials
were brought up to 50°C for 2 hr to
hydrolyze the hemoglobin. After cooling, 5
ml of 50% H202 was added to bleach the
solution. The solutions were neutralized
with 6 N HCI, and scintillation fluid
(Monofluor, National Diagnostic,
Manville, NJ) was added. The samples
were stored at 40C in the dark for several
days to minimize chemiluminescence and
then were counted. This set ofexperiments
was also performed with female F344 rats
and male and female Sprague-Dawley rats.
The latter were selected because they are
susceptible to tumor induction by nitrated
pyrenes and can be used in experiments
intended to compare levels ofDNA adducts
in target tissues to levels of hemoglobin
adducts. Such data will be valuable as base-
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Adduct Persistence in Vivo. Three
male F344 rats (162 ± 9 g body weight)
were gavaged with 2 mCi 1-NP (0.71
pmole) in trioctanoin. Approximately 0.5
ml blood was drawn from the orbital sinus
of each rat at the following intervals: 1, 3,
6, 8, 14, 28, 35, 42, 49, 56, 63, and 68
days. The hemoglobin was isolated as
described above, and the bound radioactiv-
ity was measured.
AdductAccumulation during Chronic
Dosing. Five male F344 rats (187 ± 5 g bw)
were gavaged every Monday, Wednesday,
and Friday for 5 weeks with NP (0.1 mCi,
0.006 mole; total dose: 1.8 mCi, 0.011
mole) in trioctanoin. Blood was drawn
weekly (0.5 ml/rat) via the orbital sinus on
Tuesdays and Thursdays; the hemoglobin
was isolated, and the bound radioactivity
was quantified.
Isolation and chromatographic analysis
of the hemoglobin adducts. The thawed
hemoglobin samples were added dropwise
to 200 ml of rapidly stirred 1% HC1 in
acetone on ice. The globin precipitate was
filtered, dried, and kept frozen at -200C
for further analysis. The acidic acetone
solution was evaporated to dryness under
reduced pressure. The residue was resus-
pended in tetrahydrofuran, the radioactiv-
ity was measured, and an aliquot was
analyzed by reverse-phase HPLC. The
heme fraction that contained radioactivity
was treated with H2SO4/ CH3OH to
derivatize the carboxylic acid groups on the
heme moiety to methyl esters, followed by
treatment with zinc acetate to form methy-
lated zinc metalloporphyrins (23-26); it
was then analyzed by HPLC. As an alterna-
tive approach, the whole hemoglobin was
treated in a similar manner; this simultane-
ously precipitates the protein and deriva-
tizes the heme moiety to the corresponding
methyl ester.
Incubations of 1-nitrosopyrene and 1-
nitropyrene-4,5-oxide with rat hemoglo-
bin in vitro. Both 1-NOP and
1-NP-4,5-oxide are 1-NP metabolites that
are known to bind to DNA. They also rep-
resent both metabolism pathways of 1-NP,
nitroreduction and ring oxidation. Freshly
isolated rat hemoglobin was incubated at
room temperature with both compounds
for 4.5 hr (27). [3H]1-NOP (0.7 pCi,
0.08 pmole) was incubated under both aer-
obic and anaerobic conditions. The anaero-
bic conditions were employed to minimize
further oxidation of 1-NOP to 1-NP.
[3H]1-NP-4,5-oxide (0.94 pCi, 0.013 pM)
was incubated under aerobic conditions
only.
StatisticalAnalysis
Each point in Figures 2 and 3A represents
the mean ± SD. Group means ± SD were
plotted with linear regression lines using
graphics software (Grapher, Version 1.75,
Golden Software, Golden, CO and
Statview II, Abacus Concepts, Berkeley,
CA). Biologic half-lives were calculated by




Because multiple adducts were observed
upon treatment of rats with 1-NP, includ-
ing only one minor adduct spot (N-dG-
AP) that was derived from nitroreduction
(12), our current efforts were directed
toward examining the nature and the ori-
gin of the other adducts. We prepared
markers derived from ring-oxidized
metabolites of 1-NP. The structures of 1-
NP-4,5-oxide-DNA adducts were
described previously (13). The 32P-finger-
prints of DNA that had been modified
with 1-NP-4,5-oxide are shown in Figure
4. By comparing chromatographic behav-
iors, we deduced that these oxide adducts
may be responsible for the formation of
some of the putative 1-NP-DNA adducts
in vivo (12). The 32P-maps ofDNA modi-
fied with 1-NP-4,5-oxide in the presence of
xanthine oxidase showed additional adduct
spots, including those observed in the
absence ofxanthine oxidase (Figure 4). The
maps of DNA modified with 1-NP-9,10-
oxide in the presence and absence of xan-
thine oxidase were more complex (Figure
4). Multiple adducts also were observed by
the 32P-postlabeling assays of DNA that
had been modified with 1-NP-x-OH (x =
3, 6, or 8, Figure 5) and trans-1-NP-4,5-
DHD in the presence of xanthine oxidase
(Figure 6).
Analysis ofHemoglobinAdducts
Fliowigthe Or Adnistration of
[3H]l-Nitropyrene to Rats
After dialysis, the hemoglobin solution was
extracted with EtOAc. A putative 1-NP
metabolite was covalently bound to the
hemoglobin as evidenced by the absence of
radioactivity in the EtOAc layer. [3H1-NP
forms hemoglobin adducts at 0.08 ±
0.05% (mean ± SD, n = 3 rats) ofthe dose
given orally in trioctanoin. The dose-
response data were obtained by measuring
the radioactivity in the whole hemoglobin
compartment (i.e., after dialysis but prior
to acidic acetone treatment). Using linear
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Figure 2. In vivo formation of 1-NP-hemoglobin
adducts as a function of a single oral dose of [3H11-NP.
The protein was isolated 24 hr after 1-NP administra-
tion. Adduct levels were calculated from the total
radioactivity bound to purified hemoglobin. All values






















Figure 3. (A) Clearance of radioactivity [3H] bound to
hemoglobin in rats after a single oral dose of [3H11-NP;
(B) accumulation of radioactivity bound to rat hemoglo-
bin after dosing with [3H11-NP three times/week. Blood
was drawn two times/week for 5 weeks; the arrow
marks the point oftermination ofthe dosing regimen.
is linear over five orders of magnitude
2 (p<0.01, r = 0.963; Figure 2).
Following the disappearance ofradioac-
tivity after administering a single dose of
[3HI1-NP, it appears that these adducts are
cleared (by first-order kinetics with a half-
life ofabout 14 days) faster than unmodified
rat erythrocytes (28,29); compare Figure
3A. Thus, these adducts would be expected
to accumulate as a result of chronic expo-
sure; this result was observed (Figure 3B).
After cessation of dosing (after 35 days),
these adducts decreased rapidly, as indi-
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Figure 4. 32P-PEI cellulose TLC maps of DNA modified with 1-NP-4,5-oxide (A,D) and
1-NP-9,10-oxide (BE) in the absence and presence of xanthine oxidase; solvent sys-
tems used for 4-D TLC (10 x 10 cm PEI cellulose plates, Brinkmann Instruments,
Westbury, NY) were: Dl, 1 M sodium phosphate, pH 6.8; D2, 2.5 M ammonium for-
mate, pH 3.5; D3, 3 M lithium formate: 7 M urea, pH 3.5; and D4, 0.8 M lithium chlo-
ride:7 M urea:0.5 M Tris-buffer, pH 8.0.
cated in Figure 3B. The rate of disappear-
ance of the adducts in Figure 3B seems to
be faster than that observed in Figure 3A.
This is likely a result ofdifferences between
acute and chronic treatment among other
factors (30).
The hemoglobin was treated with 1%
HC1 in acetone, to precipitate the globin;
this released 80% ofthe initial radioactivity
into the fraction containing the heme; the
globin had no measurable radioactivity.
Ethanol precipitation (31) of the globin,
followed by successive washings with
ethanol, ethanol-ether, and finally with
ether, indicated that the radioactivity still
remained bound tightly to the heme frac-
tion, while globin had no measurable
radioactivity. As shown in Figure 7A, using
a C18 column and a H20/MeOH gradient,
radioactive material eluted slightly after the
unmodified heme; the arrow indicates the
elution ofthe latter. This radioactive material
did not coelute with any of the known 1-
NP metabolites. We were not able to separate
A
Figure 5. 32P-PEI cellulose TLC maps of DNA modified with 1-NP-x-OH(x = 3, 6, or 8)
in the presence of xanthine oxidase; see legend to Figure 4 for details.
1-NP-t-4,5-DiolI:
Without Xanthine Oxidase
Figure 6. 32P-PEI cellulose TLC maps of DNA modified with trans-l-NP-4,5-DHD in the presence of xanthine oxi-
dase; see legend to Figure 4 for details.
the radioactivity from the dark brown heme using a reverse-phase C4 column and a
by silica gel column chromatography. H2O/CH3CN gradient containing 0.1%
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In vitro studies were performed to gain
insight into the nature of the binding and
to provide ample material for spectral
analysis. We incubated [3H] 1-NOP and
3[H] -NP-4,5-oxide with rat hemoglobin.
140 Bothcompounds bound toglobin, theformer
more so (37% of the initial radioactivity)
than the latter (25%). In addition, radioac-
tivity from both compounds was also
found to be associated with the heme frac-
tion (-20%). The in vitro results do not
exclude the possible contribution of these
_ _.1 two metabolites to adduct formation in
o so 70 ~vivo. However, we did not investigate fur-
ther whether the radioactivity that was
rua4li-ntiv ILJnin.L tn the h1M. I MAiPtA7IL 1L 1J YC
Figure 7. (A), HPLC radiochromatogram of the heme
fraction obtained by treating 1-NP-hemoglobin adducts
with 1% HCI in acetone. HPLC conditions: 0-100%
CH30H in H20 at 1 ml/min over 110 min using a Vydac
C18 column (10 p, 4.6 x 250 mm) (Separation Group,
Hesperia, CA); (B), the heme fraction was also analyzed
using the following HPLC conditions: 23-38% solvent
A in solvent B in 25 min, then to 100% B in 30 min at 2
ml/min using a Vydac large pore C4 column (10 x 250
min). Solvent A: 20% CH3CN in H20 and solvent B:
80% CH3CN in H20. Both solvents A and B contain
0.1% CF3COOH. The arrow indicates the retention time
of unmodified heme.
eluted after the unmodified heme (Figure
7B). Treatment of the radioactive fraction
with 6 and 12 N HCl, or with concen-
trated HBr, concentrated HI, or 5 and 10
N NaOH did not release a recognizable
derivative of 1-NP. In fact, such treatment
did not alter the retention time ofthe orig-
inal radioactive peak in the C18-system
(Figure 7A). This indicated that a radioac-
tive metabolite of 1-NP was covalently
bound to the heme. Following a general
procedure described by Ortiz de
Montellano (see "Materials and Methods"),
the heme fraction was derivatized to its
methyl ester by treating with 10% H2SO4
in CH3OH. This simultaneously precipi-
tated the proteins, removed the iron ligand,
and methylated the free carboxylic acid
groups on the porphyrin. The methylated
porphyrins were then isolated by extraction
and complexed with zinc using Zn(CH3
COO)2. The Zn-complex was purified by
means ofsilica gel chromatography. HPLC
analysis of the methylated Zn-complex on
a C4 column indicated the presence oftwo
major radioactive peaks that eluted slightly
later than those observed before derivatiza-
tion (data not shown). This is consistent
with ester formation. When the in vivo
experiments were repeated using [14 1-NP
instead of [3H]1-NP, similar results were
obtained. More ofthe Zn complex is needed
to enable field desorption mass spectros-
copy analysis for structural information.
similar to thatobserved in vivo.
Discussion
32P-Posdabeling Studies
It was our aim to compare qualitatively the
32P-maps from in vivo experiments with
those obtained from DNAsamples following
in vitro incubations of metabolites derived
from ring oxidation and ring oxidation
combined with nitroreduction of 1-NP.
The results suggest that such metabolites
may contribute to the formation of puta-
tive 1-NP-DNA adducts found in vivo
(12); however, confirmation is required.
Comparing our results with those obtained
by Jeffrey et al. (32) and Bond et al. (33),
who exposed rats to a source containing 1-
NP (e.g., Diesel engine emissions), should
provide insights regarding the utility ofthe
adduct markers. It was demonstrated that
animals exposed to Diesel engine emissions
had higher adduct levels in the lung than
did unexposed rats (32,33). Although the
chemical identity of these adducts has not
been determined, they were chromato-
graphically different from the major adduct
spots derived from (±)-anti-benzo[a]-
pyrene-7,8-dihydrodiol-9,10-epoxide. It is
possible that adducts derived from 1-NP
are present in the lungs of rats after expo-
sure to Diesel engine emissions; however,
the analysis of DNA from such exposed
animals and of DNA modified with
metabolites of 1-NP in vitro should be con-
ducted under identical conditions.
Hemoglobin Studies
We have ascertained that 1-NP binds to
hemoglobin ofboth male and female F344
rats in a dose-response related manner over
five orders of magnitude at a level of
0.08% of the dose; levels of binding were
the same in male and female Sprague-
Dawley rats. With the exception of 4-
aminobiphenyl binding to hemoglobin
(approximately 5%) (27), most other car-
cinogens or xenobotics studied have been
found to bind to hemoglobin at levels com-
parable to those measured in the present
study (34). Clearance ofhemoglobin-asso-
ciated radioactivity (half-life = about 14
days) upon administration ofa single dose of
1-NP occurred at a faster rate than that of
unmodified rat erythrocytes (half-life = 30
days). The clearance rate of hemoglobin
adducts varies, depending on their struc-
ture. For example, binding of hemoglobin
to ethylene oxide, dimethylnitrosamine,
vinyl chloride, methylmethane sulfonate,
benzo[a]pyrene, fluoranthene, and benzene
yields adducts that have lifetimes equiva-
lent to that of the erythrocyte life-span
(35-40). In contrast, Neumann reported
that several aromatic amines form hemo-
globin adducts that have shorter lifetimes
than that ofthe erythrocyte in the rat (41).
Carmella and Hecht have also reported a
half-life of 9.1 days for adducts formed
with metabolites of the tobacco-specific
nitrosamine 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone (42).
We attempted to elucidate the structure
of 1-NP-hemoglobin adducts. Knowledge
gained during the past decade on the
metabolism of 1-NP led us to reason ini-
tially that nitroreduction could be responsi-
ble for hemoglobin binding via formation
of 1-NOP. The latter compound would be
expected to react with cysteine residues on
hemoglobin. The adduct containing the
sulfinamide bond would be labile under
the acidic conditions used in this study for
the hydrolysis of 1-NP-hemoglobin
adducts. The acid hydrolysis ofhemoglobin
adducts revealed that none of the radioac-
tivity remained bound to the globin and
more than 80% of the initial radioactivity
was recovered in the heme fraction.
Concentrated acid and base treatments of
the heme fraction did not release any
detectable derivative of 1-NP, suggesting
that the radioactivity was strongly bound
to the heme moiety. Other compounds (for
example phenylhydrazine, 3-alkylsydnones,
diethylnitrosamine, aminobenzotriazole,
and norethindrone) have also been shown
to form adducts with the heme moiety of
hemoglobin as well as with heme-contain-
ing enzymes (23-26,43-45).
Although we have evidence to suggest
that binding of 1-NP to heme forms stable
adducts, the exact nature ofthis binding is
still unknown. To learn more about the
structure of the heme adducts, we incu-
bated [3H1-NOP and [3H]1-NP-4,5-
oxide with rat hemoglobin. In each case
tritium was bound mainly to globin and, to
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a lesser extent, to the heme moiety. These
findings contrasted with those obtained in
vivo, thus leading us to believe that these
particular metabolites are not required in
the binding of 1-NP to the heme moiety in
vivo. However, one cannot exdude the pos-
sibility that such metabolites contribute to
the in vivo binding solely on the basis ofin
vitro findings. Even though the structures
of the 1-nitropyrene-heme adducts have
not been elucidated, the fact that they are
stable may render them useful as dosimeters
for human exposure to 1-nitropyrene.
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